^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BVX001

    i
    Other names: BVX001, BVX130-mcMMAF
    Company:
    BiVictriX Therap
    Drug class:
    Microtubule inhibitor, CD33-targeted antibody-drug conjugate, CD7-targeted antibody-drug conjugate
    Related drugs:
    3ms
    A bispecific antibody-drug conjugate targeting CD7 and CD33 shows anti-tumor activity and improved tumor selectivity in an aggressive subtype of acute myeloid leukemia. (PubMed, MAbs)
    Finally, BVX001 showed significant blast ablation and reduced leukemic stem cell frequency in AML patient samples with both high and low target co-expression. Together, our findings support BVX001 as a new and promising approach for the treatment of this aggressive CD33+CD7+ AML subtype, currently lacking targeted therapeutic options.
    Journal
    |
    CD33 (CD33 Molecule) • CD7 (CD7 Molecule)
    |
    BVX001